Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Revenue		$ 41,873	$ 37,647
Operating expenses
Cost of revenue		18,051	18,681
Research and development		30,245	32,601
Sales and marketing		22,319	22,308
General and administrative		19,597	20,831
Amortization of intangible assets		423	419
Total operating expenses		90,635	94,840
Loss from operations		(48,762)	(57,193)
Interest and other income, net		4,222	3,024
Interest expense	[1]	(2,993)	(3,531)
Net loss		(47,533)	(57,700)
Add: Net loss attributable to noncontrolling interest		26	1
Net loss attributable to Adaptive Biotechnologies Corporation		$ (47,507)	$ (57,699)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic		$ (0.33)	$ (0.40)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic		145,787,527	143,511,142
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted		$ (0.33)	$ (0.40)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted		145,787,527	143,511,142

[1] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.